Invivyd, Inc.

Stocks

IVVD

US00534A1025

Market Closed - Nasdaq 16:00:00 2026-11-06 EST			5-day change	1st Jan Change
0.5630 ^USD	-3.76%		-3.21%	-77.21%

10-21	Invivyd, Inc. Presents VMS063, A Potential Best-In-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, At IDWeek 2026	CI
10-14	Invivyd, Inc. and The SPEAR Study Group Announce Initiation Of FLINTLOCK Phase 2 Study Of VYD2311, A Monoclonal Antibody For The Potential Treatment Of Long COVID Or Post-Vaccination Syndrome	CI

Transcript : Invivyd, Inc. - Special Call

Published on 09/29/2026 at 10:05 am EDT - Modified on 09/29/2026 at 12:35 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Invivyd Topline LIBERTY Data and VYD2311 Next Steps, September 29, 2026. [Operator

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Invivyd, Inc.

10-21	Invivyd, Inc. Presents VMS063, A Potential Best-In-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, At IDWeek 2026	CI
10-14	Invivyd, Inc. and The SPEAR Study Group Announce Initiation Of FLINTLOCK Phase 2 Study Of VYD2311, A Monoclonal Antibody For The Potential Treatment Of Long COVID Or Post-Vaccination Syndrome	CI
09-29	Invivyd, Inc. - Special Call
09-29	Invivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine Trial	MT
09-29	Invivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to Mrna-Based Covid-19 Vaccine and Announces Regulatory Submission Plans for VYD2311	CI
09-29	Invivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating Vyd2311 Safety and Tolerability Superior to Mrna-Based Covid-19 Vaccine	CI
09-20	Invivyd, Inc.(NasdaqGM:IVVD) added to S&P Global BMI Index	CI
09-01	Invivyd, Inc. Announces Appointment of Marc W. Elia to Chief Executive Officer, Effective August 30, 2026	CI
09-01	Invivyd, Inc. Announces Board Changes, Effective August 30, 2026	CI
09-01	Invivyd, Inc. Announces Results of VYD2311 Studies DECLARATION And LIBERTY	CI
09-01	Invivyd Names Chairman Marc Elia as CEO	MT
08-13	Invivyd, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-06	Healthcare Stocks Decline as Investors Rotate Away from Safety -- Healthcare Roundup	DJ
07-06	FDA to End Emergency Use Authorization For Invivyd's Covid-19 Prevention Shot	DJ
07-06	Invivyd, Inc. Receives Notice of Termination for Pemgarda Emergency Use Authorization and Provides Update on Next Steps with Fda	CI

Chart Invivyd, Inc.

Duration

Period

IVVD: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - Invivyd, Inc.

More financial data

Ratings

More Ratings

EPS Estimates

Evolution of Analysts' Estimates - EPS - Invivyd, Inc.

Revisions to estimates